Epperly Melissa B,

Epperly Melissa B, is a declared insider at 2 companies (finance chief); the most frequent names are Roivant Sciences Ltd. and Zentalis Pharmaceuticals, Inc. Between 3 May 2021 and 1 October 2026, the trades on record add up to 39 filings.

Market trades split into 1 purchase (€59k) and 13 sales (€2.5M). Netting one side against the other leaves €2.5M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 23 share grants and 1 option exercise. So far in 2026, the count stands at no purchases and 5 sales.

The latest filing, published on 5 October 2026, reports an option exercise of €70k in Roivant Sciences Ltd. The most recent open-market purchase was published on 20 August 2021, 1,885 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.